Decisions on how many YourPDX testing agents should be selected (treatment arms), and which anti-cancer therapies/therapeutic combinations should be tested, rest with the treating oncologist and the patient. Certis can help identify therapeutic options upon request using CertisAI, and/or by engaging members of the Certis Oncology Medical Advisory Board. You also can leverage our in-house bioinformatics team to identify off-label and investigational therapies based on tumor genetics, as therapies that work for an individual cancer patient may sometimes fall outside those approved for a particular diagnosis.